Vimarsana
Biggest News Aggregation in the World

Medical Segment News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Medical Segment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Medical Segment Today - Breaking & Trending Today

Short Interest in 1933 Industries Inc. (OTCMKTS:TGIFF) Drops By 75.6% - Vimarsana News

Short Interest in 1933 Industries Inc. (OTCMKTS:TGIFF) Drops By 75.6%

1933 Industries Inc. (OTCMKTS:TGIFF – Get Free Report) was the target of a large decline in short interest during the month of May. As of May 31st, there was short interest totalling 8,100 shares, a decline of 75.6% from the May 15th total of 33,200 shares. Based on an average daily volume of 166,600 shares, […]

Cardinal Health Reports Second Quarter Fiscal 2024 Results and Raises Fiscal 2024 Outlook - Vimarsana News

Cardinal Health Reports Second Quarter Fiscal 2024 Results and Raises Fiscal 2024 Outlook

Revenue increased 12% to $57.4 billionGAAP1 operating earnings were $482 million; GAAP diluted EPS was $1.43Non-GAAP operating earnings increased 20% to $562 million; non-GAAP diluted EPS increased...

Cardinal Health 2Q Earnings Top Views as Company Boosts FY24 Adj EPS Views - Vimarsana News

Cardinal Health 2Q Earnings Top Views as Company Boosts FY24 Adj EPS Views

By Rob Curran Cardinal Health's fiscal second-quarter operating earnings blew past Wall Street expectations and the medical supplies distributor raised its...

Cardinal Health Earnings Beat Expectations. Why the Stock is Falling. - Vimarsana News

Cardinal Health Earnings Beat Expectations. Why the Stock is Falling.

The company cut 2024 profit guidance for a unit that distributes medical supplies.

Why Is Cardinal Health Stock Trading Lower Today? - Cardinal Health (NYSE:CAH) - Vimarsana News

Why Is Cardinal Health Stock Trading Lower Today? - Cardinal Health (NYSE:CAH)

Cardinal Health reports strong Q2 FY24 results: Adjusted EPS up 38% to $1.82, beating consensus. Q2 revenue for pharmaceutical segment rises 12% to $53.5 billion. Raised FY24 EPS guidance to $7.20-$7.35.